Compounds and compositions for treating hematological disorders
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- 奥锐金肿瘤有限公司
- Publication Date
- 2020-01-14
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
[0001] Cross References to Related Applications
[0002] This application claims the benefit of priority from Indian Provisional Patent Application Serial No. 201741011785 filed on March 31, 2017, which is hereby incorporated by reference in its entirety. Background technique
[0003] Acute myeloid leukemia (hereinafter also referred to as "AML") is a hematological malignancy with a poor prognosis, usually occurring in adults, and its 5-year survival rate is estimated to be 20%. Currently, AML therapy temporarily reduces the number of AML cells to levels below the limit of detection. This condition is called a "complete remission." However, AML often relapses after complete remission, and for many patients, relapsed AML leads to death. In particular, in the case of relapse, the extremely low survival rate has been a serious concern. Therefore, new treatments for AML are needed. Contents of the invention
[0004] Provided herein is a method of treating or preventing acute...